SWM
INDV icon

Sandro Wealth Management’s Indivior Pharmaceuticals INDV Stock Holding History

Sandro Wealth Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02M Sell
73,634
-22,530
-23% -$817K 2.18% 15
2026
Q1 		$2.93M Buy
96,164
+59,579
+163% +$1.97M 2.35% 13
2025
Q4 		$1.31M Buy
+36,585
New +$1.12M 1.09% 34

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sandro Wealth Management's INDV Position: Q2 2026 in Review

Sandro Wealth Management reduced its Indivior Pharmaceuticals (INDV) stake by 23% in Q2 2026, selling an estimated $817K and leaving 73,634 shares worth $3.02M. The position accounts for 2.18% of the portfolio, ranked #15.

Sandro Wealth Management first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Sandro Wealth Management held 73,634 shares of Indivior Pharmaceuticals worth $3.02M as of Q2 2026.
  • Sandro Wealth Management sold 22,530 Indivior Pharmaceuticals shares in Q2 2026, an estimated $817K.
  • Indivior Pharmaceuticals made up 2.18% of Sandro Wealth Management's portfolio in Q2 2026, its #15 holding.
  • Sandro Wealth Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Sandro Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.